linjc16/ctgov huggingface dataset:
The PCOS Challenge Study

Study Overview
=================
Brief Summary
-----------------
The primary purpose of The PCOS Challenge Study will be to conduct high-quality research where patients are included in the design, and answering the questions that patients identify as important to their lived experience with PCOS. In partnership with clinical investigators, patients will work on the development and management of data collection, the research agenda, and the sharing of research findings. The PCOSC Study will promote the advancement of research that provides reliable, useful, and meaningful information to patients with PCOS and their clinicians. The population for The PCOS Challenge Study will include individuals with a clinical diagnosis of PCOS, individuals self-diagnosed with PCOS, individuals with symptoms of PCOS (e.g., hirsutism, irregular menstrual cycles), and demographic-matched controls without PCOS.

Official Title
-----------------
The PCOS Challenge Study: For the Collection of Information to Advance Research and Improve Care for PCOS Patients

Conditions
-----------------
Polycystic Ovary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with PCOS by a health professional, self-diagnosed with PCOS or individuals with PCOS symptoms Willing to sign the consent form Able to understand the registry surveys or what is being asked Exclusion Criteria: Unable to understand the surveys or what is being asked Unwilling to sign the consent form

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Target Population<br>The target population includes individuals diagnosed with PCOS by a healthcare provider, self-diagnosed with PCOS, or who are exhibiting PCOS Symptoms and willing to sign the consent. | |
| Control Population<br>The control population includes people born biologically female who have not been diagnosed with PCOS and who also do not have symptoms of PCOS. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Information | Such as responses to survey questions | One Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pcos, polycystic ovary syndrome, polycystic ovarian syndrome, stein leventhal syndrome
Bedside Tests of Cardiorespiratory Fitness

Study Overview
=================
Brief Summary
-----------------
A study of 64 older adults over the age of 65y to assess the utility of patient characteristics and bedside measures of physical function and muscle size to predict cardiorespiratory fitness.

Detailed Description
-----------------
A study of 64 older adults over the age of 65y to assess the utility of patient characteristics (age, gender and BMI) and bedside measures of physical function (handgrip strength and step box test) and muscle size (muscle thickness via B-mode ultrasonography (US)) to predict cardiorespiratory fitness (VO2peak and anaerobic threshold) as measured by the gold-standard assessment method, cardiopulmonary exercise testing (CPET). Each participant will take part in a single assessment day (after health screening against CPET safety criteria) whereby they will have US measures of the vastus lateralis before completing HGS and step box test assessments, and finally a CPET.

Official Title
-----------------
Exploring the Utility of Bedside Tests for Predicting Cardiorespiratory Fitness in Older Adults

Conditions
-----------------
Aging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 65y Independent, community-dwelling Exclusion Criteria: Contraindications to CPET safety criteria

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiorespiratory fitness (CRF) - VO2 max | CRF via cardiopulmonary exercise testing (CPET). This includes a measure of maximum oxygen uptake (VO2 max) determined via inline breath gas analysis during an incremental cycle test. | Single time-point - 8 to 12 minutes | 
| Cardiorespiratory fitness (CRF) - Anaerobic threshold | CRF via cardiopulmonary exercise testing (CPET). This includes a measure of anaerobic threshold (AT) determined via inline breath gas analysis during an incremental cycle test. | Single time-point - 8 to 12 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle architecture - muscle thickness | Analysis of vastus lateralis muscle thickness using b-mode ultrasonography | Single time-point: 10 minutes | 
| Muscle architecture - pennation angle | Analysis of vastus lateralis pennation angle using b-mode ultrasonography | Single time-point: 10 minutes | 
| Muscle architecture - fascicle length | Analysis of vastus lateralis fascicle length using b-mode ultrasonography | Single time-point: 10 minutes |
CKD-702 Plus Irinotecan in Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Official Title
-----------------
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: CKD-702 in combination with irinotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Failed 2 or more lines of chemotherapy Tumor overexpressing either MET or EGFR Measurable lesion Exclusion Criteria: Prior treatment with anti-MET/EGFR bispecific antibody

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CKD-702 in combination with irinotecan<br> | Drug: CKD-702 in combination with irinotecan<br>* CKD-702 and irinotecan will be intravenously administered every 2 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best objective response rate | RECIST v1.1 | Through study completion, an average of 24 weeks |
Evaluation of Vidiac Scores of Obese and Non-obese Patients Intubated by Videolaryngoscopy

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to observe the vidiac score values of only patients with obesity as a risk factor for difficult intubation. Secondly, it was aimed to evaluate the number of intubation attempts and intubation time, vidiac scores between non-obese and obese patients and to reveal the differences, if any.

Official Title
-----------------
Evaluation of Vidiac Scores of Obese and Non-obese Patients Intubated by Videolaryngoscopy

Conditions
-----------------
Vidiac Score, Videolaryngoscopy, Obesity

Intervention / Treatment
-----------------
* Diagnostic Test: Vidiac Score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients to be operated under general anesthesia and endotracheal intubation Exclusion Criteria: under 18 years old The patient's refusal Difficult airway story before Congenital or previous airway anatomical disorder Patients who have undergone airway surgery Patients with a mass in the head and neck region

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| obese<br>Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance | Diagnostic Test: Vidiac Score<br>* Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.<br>|
| non-obese<br>Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance | Diagnostic Test: Vidiac Score<br>* Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vidiac score | Vidiac score is a scoring system created according to the visibility of laryngeal structures under videoingoscopy in patients with expected difficult intubation. | during entubation |
Metabolic Syndrome and Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
Background:Metabolic syndrome is a disorder characterized by abdominal obesity,hypertension,increased triglycerides ,decreased HDL cholesterol and increased blood glucose. Accumulating evidence strongly indicates that insulin resistance and an increased amount of abdominal fat are the pathogenic factors for the characteristics of metabolic syndrome. Studies indicate that sleep apnea may be a manifestation of the metabolic syndrome. Subjects and methods:This study was conducted in the pulmonology department at kasrelainy hospital. It included 80 patients who came to the sleep lab unit for polysomnography. Each patient was subjected to full history taking including(sex,age,smoking history,presence of diabetes or hypertension),thorough clinical examination with emphasis on waist, neck&hip circumference and blood pressure measurements,Laboratory investigations including :Lipid profile& Diabetic profile(HBA1C).In addition to ESS and stop bang score questionnaire.

Official Title
-----------------
Relationship Between Metabolic Syndrome and Obstructive Sleep Apnea

Conditions
-----------------
Sleep Apnea, Metabolic Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: sleep study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients fulfilled the criteria of OSA ( obstructive sleep apnea) in the form of symptoms suggestive of OSA (daytime sleepiness/daytime fatigue/headache/snoring)and with AHI ( apnea-hyponea index) ≥5. Exclusion Criteria: Cerebro-vascular accident within the preceding 30 days. Patients on sedatives. Patients on anti-psychotics

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OSA with metabolic syndrome<br>sleep study | Diagnostic Test: sleep study<br>* over-night polysomnography<br>|
| OSA without metabolic syndrome<br>sleep study | Diagnostic Test: sleep study<br>* over-night polysomnography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictors of metabolic syndrome among OSA patients | evaluation of factors related to occurrence of metabolic syndrome in OSA such as age(in years),weight in kilograms(kg) and height in meters (m) will not be measured separately but combined to assess BMI( weight in kg/ height in m2) and oxygen saturation (O2%), evaluation of polysomnographic data and laboratory tests in the form of lipid profile in (mg/dl) and HBA1C (g/dl) | 6 months |
Papillary Thyroid Cancer and Central Lymp Node Dissection

Study Overview
=================
Brief Summary
-----------------
Papillary cancer is a disease that spreads through lymphatic ways and its treatment is surgery. We performed prophylactic central dissection in addition to bilateral total thyroidectomy in patients with bethesda 5 and bethesda 6 biopsy results. We evaluated the pathology results retrospectively.

Official Title
-----------------
Is Central Lymph Node Dissection Necessary in Suspected Papillary Thyroid Cancer and Papillary Thyroid Cancer?

Conditions
-----------------
Papillary Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - B5 and B6 biopsy results Exclusion Criteria: - lobectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reaching 100 patients was the first target | 100 patients | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
papillary thyroid cancer
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

Study Overview
=================
Brief Summary
-----------------
Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

Official Title
-----------------
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

Conditions
-----------------
Radioembolization, Radiotherapy, Cancer, Positron Emission Tomography

Intervention / Treatment
-----------------
* Diagnostic Test: 18F-Fluoromisonidazole PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with colorectal carcinoma with liver metastasis or hepatocellular carcinoma. Is not eligible for surgery Above 18 years old The patients who are referred for transarterial radioembolization treatment to Ankara University School of Medicine Department of Nuclear Medicine. Exclusion Criteria: Patients with ECOG performance score >1 Claustrophobia Life expectancy shorter than 3 months Pregnant or breast-feeding patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment group<br>Patients received radioembolization with hepatocellular cancer or colorectal cancer liver metastases | Diagnostic Test: 18F-Fluoromisonidazole PET<br>* Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demonstrate the effect of the hypoxia in the success of the radioembolization treatment | Demonstrate the effect of the hypoxia in the success of the radioembolization treatment | 08/2024 | 
| The effect of the hypoxia on the dose-response relationships and required doses to achieve treatment response in the hypoxic and non-hypoxic group. | The effect of the hypoxia on the dose-response relationships and required doses to achieve treatment response in the hypoxic and non-hypoxic group. | 08/2024 |
One Session Vs Staged Management of Calcular Obstructive Jaundice

Study Overview
=================
Brief Summary
-----------------
to compare the outcomes between doing ERCP and laparoscopic cholecystectomy in one session Vs staged management

Detailed Description
-----------------
to compare the outcomes between 3 groups: in the 1st group we will do ERCP then laparoscopic cholecystectomy in the same session, in the 2nd group we will do laparoscopic cholecystectomy then ERCP in the same session in group 3 we will do staged management

Official Title
-----------------
One Session Vs Staged Laropendoscopic Management of Calcular Obstructive Jaundice

Conditions
-----------------
Calcular Obstructive Jaundice, Gall Bladder Disease

Intervention / Treatment
-----------------
* Procedure: staged managment
* Procedure: one session ERCP then LC
* Procedure: one session LC then ERCP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 18-70 year combined CBD and gall stone stone less than 1.5 cm fit for surgery no upper abdominal surgery Exclusion Criteria: age <18 and >70 unfit for surgery stone more than 1.5 cm upper abdominal surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: staged managment<br>ERCP then interval laparoscopic cholecystectomy | Procedure: staged managment<br>* staged management<br>|
| Experimental: one session ERCP then LC<br>one session ERCP then LC | Procedure: one session ERCP then LC<br>* one session ERCP then LC<br>|
| Experimental: one session LC then ERCP<br>one session LC then ERCP | Procedure: one session LC then ERCP<br>* one session LC then ERCP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total cost | total cost in Egyptian pound | 6 months | 
| hospital stay | total hospital stay in days | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | early postoperative complications | 30 days |
Simulated-based Program for Peripheral Nerve Blocks in Anesthesia Residents

Study Overview
=================
Brief Summary
-----------------
The goal of this Simulated Based Program for Peripheral Nerve Blocks is build learning curves in anesthesia residents. The research questions are: How behave the learning curves in a simulate based training program in peripheral nerve blocks in anesthesia residents? Does the learning achieved during the program transferred to the real patient's scenario? Participants will be subjected to 10 simulated training sessions of a sciatic popliteal nerve block, subsequently their performance will be recorded and a global scale will be applied and movements will be measured. In a second stage, the same subjects will perform a block on a real patient to determine the transfer of this simulated learning.

Official Title
-----------------
Simulated-based Training Program for Peripheral Nerve Blocks Under Ultrasound, in Anesthesia Residents: Learning Curve and Transference

Conditions
-----------------
Simulated - Based Training

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Anesthesia first year residents Exclusion Criteria: Previous regional anesthesia rotation Previous training in ultrasound guided punction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| observational global rating scale scores (GRS) | At the end of the training, residents performance will be asses using a previous validated GRS (points 0-50) | Pre-intervention: first measurement before simulated-based training. During intervention: We will assess participants after each training session during 10 weeks. Post intervention: measurement once finished the protocol. Up to 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total path length (TPL) | At the end of the training, residents performance will be asses using a hands tracking motion device that measured TPL of both hand in meters | Pre-intervention: first measurement before simulated-based training. During intervention: We will assess participants after each training session during 10 weeks. Post intervention: measurement once finished the protocol. Up to 12 weeks |
Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia

Study Overview
=================
Brief Summary
-----------------
This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021. The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR and the disease severity.

Detailed Description
-----------------
51 patients were included in our study, diagnosed as Non-COVID pneumonia Inclusion criteria: PCR(polymerase chain reaction) negative for COVID. All patients of both sexes with pneumonia . Exclusion criteria: Non pulmonary infections. Post surgery patients. Renal patients. hepatic patients. Cardiac patients. Recent pulmonary embolism. Methodology in details: All patients were subjected to: Full history with emphasis on: Epidemiological features (age, gender). Risk factors (smoking, DM). Clinical presentation (cough, Fever and duration of illness). Clinical examination (local chest examination). Laboratory investigations: venous blood samples were taken to measure APR

Official Title
-----------------
Acute Phase Reactant in Non-COVID-19 Community Acquired Pneumonia

Conditions
-----------------
Pneumonia, Acute-Phase Reaction

Intervention / Treatment
-----------------
* Diagnostic Test: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 negative bacterial pneumonia Exclusion Criteria: COVID-19 positive other non-pulmonary infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Blood sampling|blood sampling to measure APR|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of APR levels in non-Covid-19 pneumonia | assessment of the level of APR and its relation to disease severity | 6 months |